Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ENPP1 | P22413 | 2/20 | 0.39 |
| ▸ | ENPP3 | O14638 | 1/20 | 0.38 |
| ▸ | ENTPD1 | P49961 | 2/20 | 0.36 |
| ▸ | P2RX1 | P51575 | 2/20 | 0.34 |
| ▸ | P2RX3 | P56373 | 2/20 | 0.34 |
| ▸ | P2RX2 | Q9UBL9 | 1/20 | 0.34 |
| ▸ | P2RY2 | P41231 | 2/20 | 0.34 |
| ▸ | P2RY1 | P47900 | 2/20 | 0.34 |
| ▸ | P2RY11 | Q96G91 | 1/20 | 0.34 |
| ▸ | P2RX4 | Q99571 | 1/20 | 0.32 |
| ▸ | RNASEL | Q05823 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19050103 | 0.88 | ENPP1 (0.41) | ENPP1ENPP3ENTPD1P2RX1P2RX3 | |
| SCHEMBL19536267 | 0.88 | ENPP1 (0.41) | ENPP1ENPP3ENTPD1P2RX1P2RX3 | |
| SCHEMBL23171493 | 0.86 | ENPP1 (0.49) | ENPP1ENPP3ENTPD1P2RX1P2RX3 | |
| SCHEMBL23171157 | 0.82 | PRMT5 (0.36) | — | |
| SCHEMBL19050058 | 0.80 | XDH (0.35) | P2RY2P2RY1P2RY11 | |
| SCHEMBL18430107 | 0.78 | P2RY2 (0.41) | ENPP1P2RY2 | |
| SCHEMBL19536264 | 0.77 | ENPP1 (0.31) | ENPP1ENPP3 | |
| SCHEMBL19993815 | 0.75 | ENPP1 (0.54) | ENPP1ENPP3ENTPD1P2RX1P2RX3 | |
| SCHEMBL17384903 | 0.74 | ENPP1 (0.37) | ENPP1ENPP3ENTPD1P2RX1P2RX3 | |
| SCHEMBL25564637 | 0.73 | ENPP1 (0.50) | ENPP1ENPP3ENTPD1P2RX1P2RX3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210106604-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | Janssen Pharmaceuticals, Inc. | 2021-04-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210106604-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | PNP, NUDT1, NT5C3B | ENPP1 44/4885ENPP3 58/4885ENTPD1 38/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.